cc-5013
Relapsed/ Refractory T-cell Malignancies
National Cancer Institute (NCI)Phase 1Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Relapsed/ Refractory T-cell Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide New York Medical College | Phase 3 | BBB |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
CYCLOSPORIN A Medical College of Wisconsin | Phase 3 | B |
Rapamycin Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Equine Atg Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 26 →
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →